Trials / Not Yet Recruiting
Not Yet RecruitingNCT06692270
Tislelizumab as Single-Agent Neoadjuvant Immunotherapy in Resectable Esophageal Squamous Cell Carcinoma
Tislelizumab as Single-Agent Neoadjuvant Immunotherapy in Resectable Esophageal Squamous Cell Carcinoma: A Single-Arm, Phase II Clinical Study（TISNEOS）
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Fujian Cancer Hospital · Other Government
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Tislelizumab in resectable esophageal squamous cell carcinoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tislelizumab | Tislelizumab 200mg Q3W, D1 ; 2 cycles |
Timeline
- Start date
- 2025-05-15
- Primary completion
- 2026-01-10
- Completion
- 2027-01-10
- First posted
- 2024-11-18
- Last updated
- 2025-02-28
Source: ClinicalTrials.gov record NCT06692270. Inclusion in this directory is not an endorsement.